Salvatore Parisi

Salvatore Parisi

Auto-generated profile, based on publicly available information

Salvatore Parisi

Lourdes Matha Institute of Hotel Management and Catering Technology, Kuttichal, Thiruvananthapuram, Kerala, India

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
KAKanwal Asif
Kanwal Asif
LMLorenzo Memeo
Lorenzo Memeo
SPStefano Palazzolo
Stefano Palazzolo
YFYahima Frión-Herrera
Yahima Frión-Herrera
SPSalvatore Parisi
Salvatore Parisi
FRFlavio Rizzolio
Flavio Rizzolio
Cancer is one of the major causes of death in developed countries and current therapies are based on surgery, chemotherapeutic agents, and radiation. To overcome side effects induced by chemo- and radiotherapy, in recent decades, targeted therapies have been proposed in second and even first lines. Targeted drugs act on the essential pathways involved in tumor induction, progression, and metastasis, basically all the hallmark of cancers. Among emerging pathways, the cholesterol metabolic pathway is a strong candidate for this purpose. Cancer cells have an accelerated metabolic rate and require a continuous supply of cholesterol for cell division and membrane renewal. Steroidogenic acute regulatory related lipid transfer (START) proteins are a family of proteins involved in the transfer of lipids and some of them are important in non-vesicular cholesterol transportation within the cell. The alteration of their expression levels is implicated in several diseases, including cancers. In this review, we report the latest discoveries on StAR-related lipid transfer protein domain 3 (STARD3), a member of the START family, which has a potential role in cancer, focusing on the structural and biochemical characteristics and mechanisms that regulate its activity. The role of the STARD3 protein as a molecular target for the development of cancer therapies is also discussed. As STARD3 is a key protein in the cholesterol movement in cancer cells, it is of interest to identify inhibitors able to block its activity.

10 September 2020 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
AAAlessandra Arcelli
Alessandra Arcelli
MBMilly BUWENGE
Milly BUWENGE
Gabriella MacchiaGabriella Macchia
Gabriella Macchia
FBFederica Bertini
Federica Bertini
AGAlessandra Guido
Alessandra Guido
Alessio Giuseppe MorgantiAlessio Giuseppe Morganti
Alessio Giuseppe Morganti
Conventionally fractionated chemoradiation (CRT) or chemotherapy (CHT) are considered as standard options in locally advanced pancreatic cancer (LAPC) while stereotactic body radiotherapy (SBRT) is an emerging treatment in this setting. The aim of this study was to compare two cohorts of LAPC patients treated with SBRT ± CHT vs CRT ± CHT in terms of local control (LC), distant metastases‐free survival (DMFS), progression‐free survival (PFS), overall survival (OS), and toxicity. Eighty patients were included. Patients in the two cohorts were matched according to: age ≤/>65 years, tumor diameter (two cut‐offs: </≥3.0 and </≥3.9 cm), clinical tumor stage and clinical nodal stage, neoadjuvant CHT, and adjuvant CHT. Median prescribed total dose was 30.0 Gy (range: 18.0‐37.5) and 54.0 Gy (18.0‐63.0) in SBRT and CRT cohorts, respectively. Toxicity was evaluated by CTCAE v4.0 scale. Survival curves were calculated by Kaplan‐Meier method. For hypothesis testing an equivalence and a non‐inferiority test was calculated. No statistically significant differences in terms of acute and late toxicity, DMFS, PFS, and OS were recorded among the two cohorts. Median, 1‐, and 2‐year LC was: 16.0 months, 53.1%, and 40.5% in the CRT cohort and 22.0 months, 80.4%, and 49.8% in the SBRT cohort, respectively (P: .017). A statistically non‐inferiority significance was recorded in terms of OS between CRT and SBRT (P = .031). Patients treated with SBRT showed higher LC rate and similar OS compared to CRT. Therefore, the design of confirmatory randomized studies comparing SBRT and CRT seems justified.

22 October 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RFRossella Farra
Rossella Farra
MMMatea Maruna
Matea Maruna
FPFrancesca Perrone
Francesca Perrone
MGMario Grassi
Mario Grassi
Fabio BenedettiFabio Benedetti
Fabio Benedetti
Gabriele GrassiGabriele Grassi
Gabriele Grassi
The unmet need for novel therapeutic options for ovarian cancer (OC) deserves further investigation. Among the different novel drugs, small interfering RNAs (siRNAs) are particularly attractive because of their specificity of action and efficacy, as documented in many experimental setups. However, the fragility of these molecules in the biological environment necessitates the use of delivery materials able to protect them and possibly target them to the cancer cells. Among the different delivery materials, those based on polymers and lipids are considered very interesting because of their biocompatibility and ability to carry/deliver siRNAs. Despite these features, polymers and lipids need to be engineered to optimize their delivery properties for OC. In this review, we concentrated on the description of the therapeutic potential of siRNAs and polymer-/lipid-based delivery systems for OC. After a brief description of OC and siRNA features, we summarized the strategies employed to minimize siRNA delivery problems, the targeting strategies to OC, and the preclinical models available. Finally, we discussed the most interesting works published in the last three years about polymer-/lipid-based materials for siRNA delivery.

31 August 2023 in Current Research in Nutrition and Food Science Journal
Verified
Journal Article
Open access
PDF file
Moawiya A HADDADMoawiya A HADDAD
Moawiya A HADDAD
S–Sati Y. Al –Dalain
Sati Y. Al –Dalain
AAAhmad Al-Fraihat
Ahmad Al-Fraihat
SPSalvatore Parisi
Salvatore Parisi
CPCarmelo Parisi
Carmelo Parisi
Samer AlqaralehSamer Alqaraleh
Samer Alqaraleh
Pumpkin has particular health properties for patients suffering from chronic diseases as it is considered an excellent and low-cost source of phytochemicals, antioxidant properties, vitamins and minerals, anti-inflammatory properties, and low in calories. This study aimed to fortify chicken sausage with various ratios (15, 30, and 45%) of fresh pumpkin pulp to prevent lipid oxidation during cold storage. Sensory evaluation indicated that the sample fortified with 30% pumpkin is the most favorite and nearest to the control sample. It improved taste and texture as compared to other treatments. Its moisture contents were higher than that of the control group, leading to minimizing the caloric value (25%). Seventeen amino acids were found that were similar to the control sample. Still, the ratio between total essential amino acids and total amino acids in fortified samples was 1.04-fold higher compared to the control sample. A similar trend was also detected when the ratio between saturated and unsaturated fatty acids was calculated. Results showed that this new product has functional, healthy properties for patients suffering from chronic diseases.